- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00155194
Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice
September 9, 2005 updated by: National Taiwan University Hospital
Impaired T-Lymphocyte Proliferative Function in Biliary Atresia Children With Prolonged Jaundice
Null hypothesis of this study: Biliary atresia patients with cholestatic jaundice do not have systemic immunity defect.
Study Overview
Status
Unknown
Conditions
Detailed Description
Biliary atresia patients with cholestatic jaundice were noted to have increased incidence of infectious complications.
Previous animal models of bile duct ligation with acute jaundice ever demonstrated impairment of both humoral and cellular immune function.
We performed the immunity study in biliary atresia patients due to the lack of comprehensive systemic immunity study in pediatric cholestatic model.
Systemic humoral immunity (total serum IgG, IgA, IgM, C3 and C4), specific cellular immunity (lymphocyte classification, mitogen response, cytokines level after PHA stimulation test), and non-specific cellular immunity (absolute neutrophil count, PMN CD11b/CD18 expression level, PMN superoxide release function, and PMN phagocytosis function) were tested.
Association with serum bilirubin level, nutritional status and blood biochemical values were tested to see the relation between systemic immune function and cholestatic jaundice.
Study Type
Observational
Enrollment
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jia-Feng Wu, MD
- Phone Number: 5451 886-2-23123456
- Email: water@ha.mc.ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- Department of Pediatrics, National Taiwan University Hospital
-
Contact:
- Jia-Feng Wu, MD
- Phone Number: 5451 886-2-23123456
- Email: water@ha.mc.ntu.edu.tw
-
Contact:
- Yen-Hsuan Ni, MD
- Phone Number: 5451 886-2-23123456
- Email: yhni@ha.mc.ntu.edu.tw
-
Principal Investigator:
- Jia-Feng Wu, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Biliary patients older than 1-year-old status post Kasai operation.
Exclusion Criteria:
Received liver transplantation, immunosuppresant, systemic immunoglobulin (within 6 months) and obvious infectious episode (within 2 weeks).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Mei-Hwei Chang, MD, Department of Pediatrics, Natonal Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2004
Study Registration Dates
First Submitted
September 9, 2005
First Submitted That Met QC Criteria
September 9, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
September 12, 2005
Last Update Submitted That Met QC Criteria
September 9, 2005
Last Verified
June 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9361701170
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Atresia
-
Sarah Magdy AbdelmohsenCompleted
-
RenJi HospitalUnknownBiliary Atresia Intrahepatic Syndromic FormChina
-
Children's Hospital of Fudan UniversityCompletedBiliary Atresia Congenital Type 3China
-
Yonsei UniversityCompletedBiliary Atresia, Kasai Portoenterostomy Status
-
Institute of Liver and Biliary Sciences, IndiaUnknownPortal Hypertension, Biliary AtresiaIndia
-
Intercept PharmaceuticalsNot yet recruiting
-
Weibing TangRecruiting
-
Holterman, Ai-Xuan, M.D.T Rose Clinical, Inc.; Big Leap Research; Prometheus USARecruitingBiliary AtresiaUnited States, Vietnam, Pakistan
-
AlbireoRecruitingBiliary AtresiaNetherlands, United States, Spain, Italy, Taiwan, Korea, Republic of, France, Germany, United Kingdom, Canada, Belgium, China, Australia, Poland, Turkey, Malaysia, New Zealand, Hungary, Israel
-
Arbor Research Collaborative for HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting